Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 72

Sort by

Sort Order Select

Journal Articles

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study

Jian Huang, Tian Zeng, Xiudi Yang, Xingli Zhao, Guangxun Gao, Hu Zhou, Hongyan Tong

Blood (2025) 146 (Supplement 1): 2034.

https://doi.org/10.1182/blood-2025-2034

Published: 2025

Journal Articles

Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML

Rumeng Li, Qingmei Han, Tian Zeng, Jiansong Huang, Jian Huang

Blood (2025) 146 (Supplement 1): 7270.

https://doi.org/10.1182/blood-2025-7270

Published: 2025

Journal Articles

Targeting DNA repair vulnerabilities to eradicate TP53 mutated AML.

Rifat Najnin, Stacia Octaviani, Jian Huang, Tomasz Skorski

Blood (2025) 146 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2025-1498

Published: 2025

Journal Articles

Targeting ribonucleotide reductase to overcome FLT3 Inhibitor Resistance in acute myeloid leukemia

Jian Huang

Blood (2025) 146 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2025-1492

Published: 2025

Journal Articles

Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms

Qingmei Han, Rumeng Li, Bingbing Wen, Tian Zeng, Zhikang Zheng, Xiaojing Bao, Xiudi Yang, Jian Huang

Blood (2025) 146 (Supplement 1): 7286.

https://doi.org/10.1182/blood-2025-7286

Published: 2025

Journal Articles

Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors

Qingmei Han, Rumeng Li, Bingbing Wen, Tian Zeng, Zhikang Zheng, Xiaojing Bao, Xiudi Yang, Jian Huang

Blood (2025) 146 (Supplement 1): 7276.

https://doi.org/10.1182/blood-2025-7276

Published: 2025

Journal Articles

ASXL1 and NOTCH1 mutations independently predict TKI treatment failure in chronic myeloid leukemia

Tian Zeng, Xiudi Yang, Rumeng Li, Qingmei Han, Bingbing Wen, Zhikang Zheng, Xiaojing Bao, Jian Huang

Blood (2025) 146 (Supplement 1): 5551.

https://doi.org/10.1182/blood-2025-5551

Published: 2025

Journal Articles

Single-cell profiling reveals MDSC-driven immunosuppressive remodeling of the tumor microenvironment mediates ruxolitinib resistance in myelofibrosis

Xiaoyan Ma, Bingbing Wen, Tian Zeng, Rumeng Li, Qingmei Han, Jian Huang

Blood (2025) 146 (Supplement 1): 7277.

https://doi.org/10.1182/blood-2025-7277

Published: 2025

Journal Articles

Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study

Xiaojing Bao, Tian Zeng, Zhikang Zheng, Bingbing Wen, Rumeng Li, Hongyan Tong, Jie Jin, Jian Huang

Blood (2025) 146 (Supplement 1): 7352.

https://doi.org/10.1182/blood-2025-7352

Published: 2025

Journal Articles

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Jian Huang, Bingbing Wen, Tiejun Gong, Hu Zhou, Qingchi Liu, Lihong Shou, Feng Zhang, Cuicui Wu, Wei Yang, Lidong Zhao, Lili Chen, Jian Lu, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 7351.

https://doi.org/10.1182/blood-2025-7351

Published: 2025

Journal Articles

Benchmark evaluation of large language models in acute myeloid leukemia prognosis

Xiangjie Lin, Di Xu, Nanfang Zhuo, Jingrui Jin, Yujia Wang, Liping Mao, Yinjun Lou, Min Yang, Haitao Meng, Wanzhuo Xie, Jian Huang, Hongyan Tong, Shengli Xue, Yu Zhu, Jie Jin, Jun Wang, Huafeng Wang

Blood (2025) 146 (Supplement 1): 7954.

https://doi.org/10.1182/blood-2025-7954

Published: 2025

Journal Articles

Multiple ASXL1 mutations and G646fs alterations confer increased risk of leukemic Transformation in patients with myelofibrosis

Tian Zeng, Rumeng Li, Bingbing Wen, Qingmei Han, Zhikang Zheng, Xiaojing Bao, Jian Huang

Blood (2025) 146 (Supplement 1): 3800.

https://doi.org/10.1182/blood-2025-3800

Published: 2025

Journal Articles

The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, controll trial

Bingbing Wen, Junchong Peng, Bingcheng LIU, Jian Huang, Xin Du

Blood (2025) 146 (Supplement 1): 3779.

https://doi.org/10.1182/blood-2025-3779

Published: 2025

Journal Articles

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

Jian Huang, Rumeng Li, Tiejun Gong, Pengxiang Guo, Lihong Shou, Hu Zhu, Zongjiu Jiao, Feng Zhang, Qingchi Liu, Lidong Zhao, Guocai Wu, Lili Chen, Yile Zhou, Yi Zhang, Jie Jin

Blood (2025) 146 (Supplement 1): 5530.

https://doi.org/10.1182/blood-2025-5530

Published: 2025

Journal Articles

A novel strategy to circumvent venetoclax resistance in relapsed/refractory Acute Myeloid Leukemia

Huafeng Wang, Yile Zhou, Xiang Zhang, Liping Mao, Xia Li, Xingnong Ye, Mixue Xie, De Zhou, Xiudi Yang, Jian Huang, Wenjuan Yu, Juying Wei, Min Yang, Yinjun Lou, Yanhong Tong, Jie Jin

Blood (2025) 146 (Supplement 1): 3464.

https://doi.org/10.1182/blood-2025-3464

Published: 2025

Journal Articles

Targeting mitophagy through PINK1 splicing sensitizes myeloid malignancies to venetoclax

Xiaolei Liu, Chenchen Li, Justin Wang, Andrey Poleshko, Harry Yang, Morgan Grace, Jian Huang, Alessia Angelin, Douglas Wallace, Yi Xing, Peter Klein

Blood (2025) 146 (Supplement 1): 6803.

https://doi.org/10.1182/blood-2025-6803

Published: 2025

Journal Articles

Expansion of human hematopoietic stem cells by inhibiting translation

Chenchen Li, Hanna Shin, Dheeraj Bhavanasi, Xiaolei Liu, Mai Liu, Yu Xiang, Scott Peslak, Friederike Herbst, Mohamad-Gabriel Alameh, Laura Breda, Stefano Rivella, Juan Alvarez-Dominguez, Gerd Blobel, Brian Gregory, Jian Huang, Peter Klein

Blood (2025) 146 (Supplement 1): 1379.

https://doi.org/10.1182/blood-2025-1379

Published: 2025

Journal Articles

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Yiyi Yao, Yile Zhou, Nanfang Zhuo, Wanzhuo Xie, Haitao Meng, Yinjun Lou, Liping Mao, Hongyan Tong, Jiejing Qian, Min Yang, Wenjuan Yu, De Zhou, Jian Huang, Jie Jin, Huafeng Wang

Blood (2024) 144 (Supplement 1): 7485.

https://doi.org/10.1182/blood-2024-204411

Published: 2024

Journal Articles

Machine Learning Approach Identifies a Novel Ferroptosis‐Related Gene Model in Aberrant DNA Methylation for Predicting the Progressive Risk of Primary Myelofibrosis

Bingbing Wen, Jian Huang

Blood (2024) 144 (Supplement 1): 6571.

https://doi.org/10.1182/blood-2024-205500

Published: 2024

Journal Articles

A Novel JAK2 Inhibitor OB756 Inhibits Megakaryopoiesis Differentiation and Proplatelet Biogenesis in Thrombocythemia and Polycythemia Vera

Bingbing Wen, Jiansong Huang, Jian Huang

Blood (2024) 144 (Supplement 1): 6583.

https://doi.org/10.1182/blood-2024-205441

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

BCL-2 inhibitor TQB3909 combined with JAK inhibitors in patients with intermediate- or high-risk myelofibrosis: A two-cohort, open-label, Phase ib/II, multicenter study

Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML

Targeting DNA repair vulnerabilities to eradicate TP53 mutated AML.

Targeting ribonucleotide reductase to overcome FLT3 Inhibitor Resistance in acute myeloid leukemia

Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms

Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors

ASXL1 and NOTCH1 mutations independently predict TKI treatment failure in chronic myeloid leukemia

Single-cell profiling reveals MDSC-driven immunosuppressive remodeling of the tumor microenvironment mediates ruxolitinib resistance in myelofibrosis

Integrating clinical features, long-term Outcomes and NGS-based mutational analysis in AYA patients with essential Thrombocythemia and polycythemia vera: A Multicenter Retrosepective study

Indirect treatment comparison of novel JAK2 Inhibitor OB756 versus ruxolitinib in polycythaemia vera with splenomegaly

Benchmark evaluation of large language models in acute myeloid leukemia prognosis

Multiple ASXL1 mutations and G646fs alterations confer increased risk of leukemic Transformation in patients with myelofibrosis

The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, controll trial

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

A novel strategy to circumvent venetoclax resistance in relapsed/refractory Acute Myeloid Leukemia

Targeting mitophagy through PINK1 splicing sensitizes myeloid malignancies to venetoclax

Expansion of human hematopoietic stem cells by inhibiting translation

A Novel Prognostic Model for Adult Acute Myeloid Leukemia Patients with NPM1 Mutation

Machine Learning Approach Identifies a Novel Ferroptosis‐Related Gene Model in Aberrant DNA Methylation for Predicting the Progressive Risk of Primary Myelofibrosis

A Novel JAK2 Inhibitor OB756 Inhibits Megakaryopoiesis Differentiation and Proplatelet Biogenesis in Thrombocythemia and Polycythemia Vera

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only